Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects

MLA

Wu Wei, et al. “Cytochrome CYP2C19 Polymorphism and Risk of Adverse Clinical Events in Clopidogrel-Treated Patients: A Meta-Analysis Based on 23,035 Subjects.” Archives of Cardiovascular Diseases, vol. 106, Oct. 2013, pp. 517–27. EBSCOhost, https://doi.org/10.1016/j.acvd.2013.06.055.

APA

Wu Wei, Huang Dan, Huang Suihua, Liu Changzhi, Tang Wenyi, Liu Mao, & Chen Jian. (2013). Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Archives of Cardiovascular Diseases, 106, 517–527. https://doi.org/10.1016/j.acvd.2013.06.055

Chicago

Wu Wei, Huang Dan, Huang Suihua, Liu Changzhi, Tang Wenyi, Liu Mao, and Chen Jian. 2013. “Cytochrome CYP2C19 Polymorphism and Risk of Adverse Clinical Events in Clopidogrel-Treated Patients: A Meta-Analysis Based on 23,035 Subjects.” Archives of Cardiovascular Diseases 106 (October): 517–27. doi:10.1016/j.acvd.2013.06.055.